Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition

Blood. 2016 Apr 28;127(17):2155-7. doi: 10.1182/blood-2015-12-686782. Epub 2016 Feb 16.

Authors

Marc S Raab¹, Nicola Lehners¹, Jing Xu¹, Anthony D Ho², Peter Schirmacher³, Hartmut Goldschmidt⁴, Mindaugas Andrulis³

Affiliations

¹ Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany; German Cancer Research Center, Heidelberg, Germany;
² Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany;
³ Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany; and.
⁴ Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, Heidelberg, Germany.

PMID: 26884375
DOI: 10.1182/blood-2015-12-686782

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Agents / therapeutic use*
Clonal Evolution / drug effects
Drug Resistance, Neoplasm
Female
Humans
Indoles / therapeutic use*
Middle Aged
Multiple Myeloma / drug therapy*
Multiple Myeloma / genetics*
Multiple Myeloma / pathology
Point Mutation
Protein Kinase Inhibitors / therapeutic use
Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
Proto-Oncogene Proteins B-raf / genetics
Sulfonamides / therapeutic use*
Vemurafenib

Substances

Antineoplastic Agents
Indoles
Protein Kinase Inhibitors
Sulfonamides
Vemurafenib
BRAF protein, human
Proto-Oncogene Proteins B-raf